TABLE 1.

Patient distribution with different grades and clinical features.

Features	Grade II (n=17)	Grade III (n=6)	Grade IV (n=23)
Sex
Male	13	4	11
Female	4	2	12
Age
Median (range)	34 (19–50)	52 (33–67)	52 (12–85)
Treatment
Before surgery
Chemotherapy	0	1	0
Radiotherapy	0	1	1
After surgery
Chemotherapy	13	6	19
Radiotherapy	2	1	5
Molecular
MGMT promoter
Methylated	12	3	14
Unmethylated	5	3	7
Unknown	0	0	2
IDH status
Wildtype	4	2	22
Mutant	13	4	1
Analytical platform
WES	17	6	23
RNAseq	10	3	14